Advisory Research’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Advisory Research’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-188,971	Closed	-$208	–	509
2023 Q2	$208	Sell	188,971 -13,920	-7%	-$253	﹤0.01%	436
2023 Q1	$3.85K	Hold	202,891	–	–	﹤0.01%	347
2022 Q4	$30.2K	Sell	202,891 -5,000	-2%	-$799	﹤0.01%	355
2022 Q3	$35K	Sell	207,891 -5,660	-3%	-$830	﹤0.01%	334
2022 Q2	$28K	Hold	213,551	–	–	﹤0.01%	335
2022 Q1	$169K	Hold	213,551	–	–	0.01%	342
2021 Q4	$128K	Buy	+213,551	New	+$217K	0.01%	312

Advisory Research's PEARW Position: Q3 2023 in Review

Advisory Research sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q3 2023, closing a stake of 188,971 shares — an estimated $208 sold.

Advisory Research first reported a position in PEARW in Q4 2021 and held it in 7 quarters. The position peaked at $169K in Q1 2022. 0 funds tracked by Wall St. Rank hold PEARW as of Q3 2023.

Advisory Research reported no remaining Pear Therapeutics, Inc. Warrant position as of Q3 2023 after selling out during the quarter.
Advisory Research sold 188,971 Pear Therapeutics, Inc. Warrant shares in Q3 2023, an estimated $208.
Advisory Research first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 7 quarters.
Advisory Research's Pear Therapeutics, Inc. Warrant position peaked at $169K in Q1 2022.
0 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q3 2023.

Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.